Fiche publication
Date publication
février 2022
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PREVOST Alain
,
Pr WESTEEL Virginie
Tous les auteurs :
Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S
Lien Pubmed
Résumé
ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a rare lung cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (TKIs) included small numbers of patients and real-world data are lacking. We investigate the efficacy and safety of lorlatinib, a third-generation TKI targeting ALK and ROS1, in patients with ROS1+ NSCLC treated through an expanded access program.
Mots clés
NSCLC, ROS1, brain metastases, chemotherapy
Référence
ESMO Open. 2022 Feb 25;7(2):100418
